Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tesaro, Inc.
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Seagen Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
AstraZeneca
Merck Sharp & Dohme LLC
AbbVie
AstraZeneca
Eisai Inc.
AstraZeneca
Checkpoint Therapeutics, Inc.
AstraZeneca
Verastem, Inc.
ImmunoGen, Inc.
Seagen Inc.
pharmaand GmbH
Tesaro, Inc.
On Target Laboratories, LLC
Gilead Sciences
National Cancer Institute (NCI)